

F.2	Doxorubicin, pegylated liposomal – injection 2 mg/mL – EML and EMLc
Draft recommendation	<input checked="" type="checkbox"/> Recommended <input type="checkbox"/> Not recommended <p>Justification: Liposomal doxorubicin has a longer half-life, less toxicity in non-target organs, and higher tumour concentrations of drugs.</p> <p>Survival is similar to other chemotherapy drugs already approved by EML.</p>
Does the proposed medicine address a relevant public health need?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Not applicable <p>Comments</p>
Does adequate evidence exist for the efficacy/effectiveness of the medicine for the proposed indication? (this may be evidence included in the application, and/or additional evidence identified during the review process)	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Not applicable <p>Comments:</p>
Does adequate evidence exist for the safety/harms associated with the proposed medicine? (this may be evidence included in the application, and/or additional evidence identified during the review process)	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Not applicable <p>Comments: It has fewer side effects than paclitaxel and other drugs which are already on the EML list.</p>
Are there any adverse effects of concern, or that may require special monitoring?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No <input type="checkbox"/> Not applicable <p>Comments: Less hematologic toxicities, less alopecia</p>

24th WHO Expert Committee on Selection and Use of Essential Medicines
Expert review

<p>Are there any special requirements for the safe, effective and appropriate use of the medicines?</p> <p>(e.g. laboratory diagnostic and/or monitoring tests, specialized training for health providers, etc)</p>	<p><input type="checkbox"/> Yes</p> <p><input checked="" type="checkbox"/> No</p> <p><input type="checkbox"/> Not applicable</p> <p>Comments:</p>
<p>Are there any issues regarding cost, cost-effectiveness, affordability and/or access for the medicine in different settings?</p>	<p><input type="checkbox"/> Yes</p> <p><input checked="" type="checkbox"/> No</p> <p><input type="checkbox"/> Not applicable</p> <p>Comments: generics are available making liposomal doxorubicin more cost effective. MSF is already helping in Africa</p>
<p>Are there any issues regarding the registration of the medicine by national regulatory authorities?</p> <p>(e.g. accelerated approval, lack of regulatory approval, off-label indication)</p>	<p><input type="checkbox"/> Yes</p> <p><input checked="" type="checkbox"/> No</p> <p><input type="checkbox"/> Not applicable</p> <p>Comments:</p>
<p>Is the proposed medicine recommended for use in a current WHO guideline?</p> <p>(refer to: https://www.who.int/publications/who-guidelines)</p>	<p><input checked="" type="checkbox"/> Yes</p> <p><input type="checkbox"/> No</p> <p><input type="checkbox"/> Not applicable</p> <p>Comments:</p>